JP2020172502A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020172502A5 JP2020172502A5 JP2020112519A JP2020112519A JP2020172502A5 JP 2020172502 A5 JP2020172502 A5 JP 2020172502A5 JP 2020112519 A JP2020112519 A JP 2020112519A JP 2020112519 A JP2020112519 A JP 2020112519A JP 2020172502 A5 JP2020172502 A5 JP 2020172502A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- antibody
- administered
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562188404P | 2015-07-02 | 2015-07-02 | |
| US62/188,404 | 2015-07-02 | ||
| US201562245916P | 2015-10-23 | 2015-10-23 | |
| US62/245,916 | 2015-10-23 | ||
| US201662308055P | 2016-03-14 | 2016-03-14 | |
| US62/308,055 | 2016-03-14 | ||
| US201662340972P | 2016-05-24 | 2016-05-24 | |
| US62/340,972 | 2016-05-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568243A Division JP6727237B2 (ja) | 2015-07-02 | 2016-07-01 | 血液がん及び固形腫瘍の治療のための併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020172502A JP2020172502A (ja) | 2020-10-22 |
| JP2020172502A5 true JP2020172502A5 (enExample) | 2021-02-12 |
Family
ID=56418624
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568243A Expired - Fee Related JP6727237B2 (ja) | 2015-07-02 | 2016-07-01 | 血液がん及び固形腫瘍の治療のための併用療法 |
| JP2020112519A Pending JP2020172502A (ja) | 2015-07-02 | 2020-06-30 | 血液がん及び固形腫瘍の治療のための併用療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568243A Expired - Fee Related JP6727237B2 (ja) | 2015-07-02 | 2016-07-01 | 血液がん及び固形腫瘍の治療のための併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10973822B2 (enExample) |
| EP (1) | EP3316888A1 (enExample) |
| JP (2) | JP6727237B2 (enExample) |
| KR (1) | KR20180023968A (enExample) |
| AU (1) | AU2016288246A1 (enExample) |
| BR (1) | BR112017028530A2 (enExample) |
| CA (1) | CA2991164A1 (enExample) |
| EA (1) | EA201890199A1 (enExample) |
| MX (1) | MX2018000216A (enExample) |
| WO (1) | WO2017004532A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016342039B2 (en) | 2015-10-21 | 2023-03-09 | Teclison, Inc. | Compositions and methods for immune-mediated cancer therapy |
| MX2018006779A (es) | 2015-12-02 | 2018-08-01 | Celgene Corp | Terapia ciclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-p iperidin-2,6-diona. |
| IL320372A (en) | 2016-10-28 | 2025-06-01 | Morphosys Ag | Combination of anti-CD19 antibody with BCL-2 inhibitor and uses thereof |
| US11723975B2 (en) | 2017-05-30 | 2023-08-15 | Bristol-Myers Squibb Company | Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody |
| EP3638236A1 (en) | 2017-06-12 | 2020-04-22 | Agios Pharmaceuticals, Inc. | Methods of treating brain tumors using combination therapy |
| TWI830700B (zh) | 2017-06-12 | 2024-02-01 | 法商施維雅藥廠 | 以組合療法治療腦瘤之方法 |
| US20200262919A1 (en) * | 2017-10-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Compositions and methods for treating diffuse large b cell lymphoma |
| EP3706785B1 (en) * | 2017-11-10 | 2025-08-06 | Actinium Pharmaceuticals, Inc. | Combination of radionuclide-conjugated antibodies for treatment of a hematological malignancies |
| JP2021532140A (ja) * | 2018-07-30 | 2021-11-25 | アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３３及びｃｄ３に結合する二重特異性抗体コンストラクトの長期投与 |
| JP7455822B2 (ja) * | 2019-05-21 | 2024-03-26 | クラレノリタケデンタル株式会社 | 光学的立体造形用樹脂組成物 |
| WO2021041669A1 (en) * | 2019-08-30 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Immune signatures predictive of response to pd-1 blockade in richter's transformation |
| US11839619B2 (en) * | 2019-09-16 | 2023-12-12 | The Regents Of The University Of California | Methods for treatment of pediatric systemic mastocytosis |
| CA3157106A1 (en) * | 2019-11-05 | 2021-05-14 | Scott I. ABRAMS | Combination therapy for cancer |
| US20230042129A1 (en) * | 2019-12-11 | 2023-02-09 | Erasmus University Medical Center Rotterdam | Method for Monitoring of Deep Remissions in Multiple Myeloma and Other Plasma Cell Dyscrasias |
| US20220117929A1 (en) * | 2020-10-21 | 2022-04-21 | Buddhist Tzu Chi Medical Foundation | Method for preventing or treating high-grade serous carcinoma |
| WO2023077090A1 (en) * | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
| AU2022426699A1 (en) | 2021-12-30 | 2024-07-11 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| CN115137731B (zh) * | 2022-05-19 | 2023-11-21 | 上海交通大学医学院附属新华医院 | Flt3抑制剂及其药学上可接受的盐在制备治疗皮肤t细胞淋巴瘤药物中的应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| EP2439273B1 (en) | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| RS52349B (sr) | 2006-09-26 | 2012-12-31 | Celgene Corporation | 5-supstituisani derivati hinazolinona kao antitumorski agensi |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| NZ584425A (en) | 2007-09-26 | 2012-03-30 | Celgene Corp | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| MX2011003195A (es) | 2008-09-26 | 2011-08-12 | Dana Farber Cancer Inst Inc | Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos. |
| US8217149B2 (en) | 2008-12-09 | 2012-07-10 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| RU2017120977A (ru) | 2011-03-11 | 2018-11-15 | Селджин Корпорейшн | Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона |
| CA2829570C (en) | 2011-03-11 | 2019-05-07 | Celgene Corporation | Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
| EP2892887B1 (en) | 2012-09-04 | 2020-07-15 | Celgene Corporation | Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof |
| KR20150054962A (ko) * | 2012-09-10 | 2015-05-20 | 셀진 코포레이션 | 국소 진행성 유방암의 치료방법 |
| EP2943201B2 (en) | 2013-01-14 | 2020-07-29 | Deuterx, LLC | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| RU2015151359A (ru) | 2013-05-01 | 2017-06-06 | Селджин Корпорейшн | Синтез 3-(5-амино-2-метил-4-оксохиназолин-3(4н)-ил)пиперидин-2, 6-диона |
| WO2014179661A1 (en) * | 2013-05-03 | 2014-11-06 | Celgene Corporation | Methods for treating cancer using combination therapy |
| EA201690912A1 (ru) | 2013-11-05 | 2016-10-31 | Когнейт Биосервисис, Инк. | Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака |
| WO2015108889A1 (en) | 2014-01-15 | 2015-07-23 | Celgene Corporation | Formulations of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
| AU2015287694A1 (en) | 2014-07-11 | 2017-02-02 | Celgene Corporation | Combination therapy for cancer |
| ES2865289T3 (es) | 2015-08-27 | 2021-10-15 | Celgene Corp | Composiciones farmacéuticas que comprenden 3-(5-amino-2-metil-4-oxo-4H-quinazolin-3-il)-piperidin-2,6-diona |
| MX2018006779A (es) | 2015-12-02 | 2018-08-01 | Celgene Corp | Terapia ciclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-p iperidin-2,6-diona. |
-
2016
- 2016-07-01 US US15/741,130 patent/US10973822B2/en not_active Expired - Fee Related
- 2016-07-01 BR BR112017028530A patent/BR112017028530A2/pt not_active Application Discontinuation
- 2016-07-01 JP JP2017568243A patent/JP6727237B2/ja not_active Expired - Fee Related
- 2016-07-01 KR KR1020187002705A patent/KR20180023968A/ko not_active Withdrawn
- 2016-07-01 MX MX2018000216A patent/MX2018000216A/es unknown
- 2016-07-01 WO PCT/US2016/040718 patent/WO2017004532A1/en not_active Ceased
- 2016-07-01 AU AU2016288246A patent/AU2016288246A1/en not_active Abandoned
- 2016-07-01 EA EA201890199A patent/EA201890199A1/ru unknown
- 2016-07-01 EP EP16739642.3A patent/EP3316888A1/en not_active Withdrawn
- 2016-07-01 CA CA2991164A patent/CA2991164A1/en not_active Abandoned
-
2020
- 2020-06-30 JP JP2020112519A patent/JP2020172502A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020172502A5 (enExample) | ||
| JP6231642B2 (ja) | 多発性骨髄腫およびｎｈｌ治療用の抗ｃｄ３８抗体およびレナリドミドまたはボルテゾミブ | |
| US11826317B2 (en) | Combination therapy with notch and PD-1 or PD-L1 inhibitors | |
| US20250295869A1 (en) | Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer | |
| JP2018524347A5 (enExample) | ||
| US20240254120A1 (en) | Ep4 inhibitors and synthesis thereof | |
| JP2022121599A (ja) | 慢性リンパ性白血病の治療を目的とするｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との配合物 | |
| CN113993537A (zh) | 治疗癌症的方法 | |
| US12447150B2 (en) | Treatment of cancer by combination of immune checkpoint inhibitor and folfirinox therapy | |
| JP2005530784A5 (enExample) | ||
| JP2018524347A (ja) | 血液がん及び固形腫瘍の治療のための併用療法 | |
| JP2017525713A5 (enExample) | ||
| WO2019144126A1 (en) | Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells | |
| KR20110022608A (ko) | Ｉａｐ 저해물질에 의한 면역조절 | |
| US20210369746A1 (en) | Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer | |
| TW201815417A (zh) | Ｐｄ－１抗體與ｉｄｏ抑制劑聯合在製備抗腫瘤的藥物中的用途 | |
| WO2020241749A1 (ja) | スルホンアミド化合物と免疫調節剤を用いるがん併用療法 | |
| US20100098657A1 (en) | Method of Treating Cancer with Immunomodulatory Compounds and IgG | |
| EP3646869B1 (en) | Chemotherapy for cancer using azabicyclo compound | |
| KR20220097553A (ko) | 일차 암 치료법 후 사용하기 위한 붕소-함유 프로테아좀 저해제 | |
| US20220025061A1 (en) | Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist | |
| CA3141035C (en) | Oxathiazin_dioxide for treating, preventing, inhibiting or reducing cytokine release | |
| JP2019524780A (ja) | プロテアソーム阻害剤及び抗ｃｄ３０抗体の組み合わせ | |
| HK40125832A (en) | Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer | |
| JP2025185043A (ja) | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 |